BRPI0510564A - compostos e tautÈmeros, estereoisÈmeros, e sais farmacologicamente aceitáveis dos mesmos, composições farmacêuticas, método para preparar composições farmacêuticas, e, uso de um composto - Google Patents
compostos e tautÈmeros, estereoisÈmeros, e sais farmacologicamente aceitáveis dos mesmos, composições farmacêuticas, método para preparar composições farmacêuticas, e, uso de um compostoInfo
- Publication number
- BRPI0510564A BRPI0510564A BRPI0510564-1A BRPI0510564A BRPI0510564A BR PI0510564 A BRPI0510564 A BR PI0510564A BR PI0510564 A BRPI0510564 A BR PI0510564A BR PI0510564 A BRPI0510564 A BR PI0510564A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- compound
- art
- relates
- disclosed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 150000003839 salts Chemical class 0.000 title 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 230000009286 beneficial effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 2
- -1 1,2,4,5-tetrasubstituted imidazole Chemical class 0.000 abstract 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
Abstract
COMPOSTOS E TAUTÈMEROS, ESTEREOISÈMEROS, E SAIS FARMACOLOGICAMENTE ACEITáVEIS DOS MESMOS, COMPOSIçõES FARMACêUTICAS, MéTODO PARA PREPARAR COMPOSIçõES FARMACêUTICAS, E, USO DE UM COMPOSTO. A presente invenção diz respeito a derivados de imidazol 1,2,4,5-tetrassubstituídos como moduladores seletivos do receptor de canabinóide CB~ 1~, em particular os antagonistas do receptor de CB~ 1~ ou agonistas inversos tendo uma alta seletividade de subtipo do receptor de CB~ 1~/CB~ 2~, a métodos para a preparação destes compostos e a novos intermediários úteis para a síntese dos referidos imidazóis. A invenção também diz respeito ao uso de um composto apresentado neste relatório, para a fabricação de um medicamento dando um efeito benéfico. Um efeito benéfico é aqui apresentado ou evidente a uma pessoa habilitada na técnica, a partir do relatório descritivo e do conhecimento geral na técnica. A invenção também diz respeito ao uso de um composto da invenção para a fabricação de um medicamento para tratar ou prevenir uma doença ou condição. Mais particularmente, a invenção diz respeito a um novo uso para o tratamento de uma doença ou condição aqui descritas ou evidentes a uma pessoa habilitada na técnica, a partir do relatório descritivo e do conhecimento geral na técnica. Nas modalidades da invenção, os compostos específicos apresentados neste relatório descritivo, são usados para a fabricação de um medicamento útil no tratamento de distúrbios psiquiátricos ou neurológicos. Os compostos têm a fórmula geral (I), em que os símbolos têm os significados dados no relatório descritivo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57493904P | 2004-05-28 | 2004-05-28 | |
| EP04076619 | 2004-05-28 | ||
| PCT/EP2005/052405 WO2005118553A1 (en) | 2004-05-28 | 2005-05-26 | Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0510564A true BRPI0510564A (pt) | 2007-11-20 |
Family
ID=34970307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0510564-1A BRPI0510564A (pt) | 2004-05-28 | 2005-05-26 | compostos e tautÈmeros, estereoisÈmeros, e sais farmacologicamente aceitáveis dos mesmos, composições farmacêuticas, método para preparar composições farmacêuticas, e, uso de um composto |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1756066B1 (pt) |
| JP (1) | JP2008500994A (pt) |
| AT (1) | ATE405551T1 (pt) |
| AU (1) | AU2005250161B2 (pt) |
| BR (1) | BRPI0510564A (pt) |
| CA (1) | CA2565326A1 (pt) |
| DE (1) | DE602005009180D1 (pt) |
| DK (1) | DK1756066T3 (pt) |
| ES (1) | ES2313358T3 (pt) |
| HR (1) | HRP20080587T3 (pt) |
| IL (1) | IL178563A0 (pt) |
| NO (1) | NO20065958L (pt) |
| PL (1) | PL1756066T3 (pt) |
| PT (1) | PT1756066E (pt) |
| RU (1) | RU2354650C2 (pt) |
| SI (1) | SI1756066T1 (pt) |
| WO (1) | WO2005118553A1 (pt) |
| ZA (1) | ZA200609009B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594488C (en) * | 2005-01-10 | 2015-04-28 | University Of Connecticut | Novel heteropyrrole analogs acting on cannabinoid receptors |
| FR2908766B1 (fr) * | 2006-11-20 | 2009-01-09 | Sanofi Aventis Sa | Derives de pyrrole,leur preparation et leur utilisation en therapeutique. |
| JP2010513395A (ja) * | 2006-12-20 | 2010-04-30 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | カンナビノイド−ｃｂ１拮抗作用とアセチルコリンエステラーゼ阻害の組み合わせを示す化合物 |
| US8063062B2 (en) | 2006-12-20 | 2011-11-22 | Solvay Pharmaceuticals B.V. | Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
-
2005
- 2005-05-26 BR BRPI0510564-1A patent/BRPI0510564A/pt not_active IP Right Cessation
- 2005-05-26 DE DE602005009180T patent/DE602005009180D1/de not_active Expired - Lifetime
- 2005-05-26 WO PCT/EP2005/052405 patent/WO2005118553A1/en not_active Ceased
- 2005-05-26 JP JP2007513933A patent/JP2008500994A/ja not_active Withdrawn
- 2005-05-26 RU RU2006141835/04A patent/RU2354650C2/ru not_active IP Right Cessation
- 2005-05-26 PT PT05752773T patent/PT1756066E/pt unknown
- 2005-05-26 SI SI200530452T patent/SI1756066T1/sl unknown
- 2005-05-26 AT AT05752773T patent/ATE405551T1/de active
- 2005-05-26 DK DK05752773T patent/DK1756066T3/da active
- 2005-05-26 PL PL05752773T patent/PL1756066T3/pl unknown
- 2005-05-26 ES ES05752773T patent/ES2313358T3/es not_active Expired - Lifetime
- 2005-05-26 CA CA002565326A patent/CA2565326A1/en not_active Abandoned
- 2005-05-26 EP EP05752773A patent/EP1756066B1/en not_active Expired - Lifetime
- 2005-05-26 HR HR20080587T patent/HRP20080587T3/xx unknown
- 2005-05-26 AU AU2005250161A patent/AU2005250161B2/en not_active Ceased
-
2006
- 2006-10-15 IL IL178563A patent/IL178563A0/en unknown
- 2006-10-30 ZA ZA200609009A patent/ZA200609009B/xx unknown
- 2006-12-21 NO NO20065958A patent/NO20065958L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200609009B (en) | 2008-08-27 |
| PL1756066T3 (pl) | 2009-02-27 |
| AU2005250161B2 (en) | 2010-10-07 |
| ATE405551T1 (de) | 2008-09-15 |
| RU2354650C2 (ru) | 2009-05-10 |
| RU2006141835A (ru) | 2008-06-10 |
| SI1756066T1 (sl) | 2009-02-28 |
| HRP20080587T3 (en) | 2008-12-31 |
| EP1756066B1 (en) | 2008-08-20 |
| CA2565326A1 (en) | 2005-12-15 |
| NO20065958L (no) | 2007-02-26 |
| AU2005250161A1 (en) | 2005-12-15 |
| DK1756066T3 (da) | 2008-12-15 |
| IL178563A0 (en) | 2007-02-11 |
| WO2005118553A1 (en) | 2005-12-15 |
| EP1756066A1 (en) | 2007-02-28 |
| JP2008500994A (ja) | 2008-01-17 |
| DE602005009180D1 (de) | 2008-10-02 |
| PT1756066E (pt) | 2008-11-25 |
| ES2313358T3 (es) | 2009-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0302760D0 (sv) | New compounds | |
| NO20071660L (no) | Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer | |
| PL1716152T3 (pl) | Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych | |
| EA201000331A1 (ru) | 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны | |
| EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
| UA83862C2 (ru) | Производные тиазола как модуляторы рецепторов канабиноидов | |
| NO20083500L (no) | 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
| NO20060774L (no) | Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer | |
| EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
| EA201000332A1 (ru) | 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны | |
| WO2004069794A3 (en) | New arylpiperazinyl compounds | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| MY129355A (en) | Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists | |
| ATE297929T1 (de) | Azabicycloalkan-derivate zur verwendung als inhibitoren der serotonin-wiederaufnahme und als 5ht2a antagonisten | |
| UA88910C2 (ru) | Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения | |
| NO20065958L (no) | Tetrasubstituerte imidazolderivater som cannabinoid CB1 reseptormodulatorer med en hoy CB1/CB2 reseptor undertype selektivitet | |
| NO20062249L (no) | 1H-imidazolderivater som cannabionidreseptor modulatorer | |
| DK1373218T3 (da) | Imidazolylderivater til anvendelse som histamin H3-receptorligander | |
| DK1517909T3 (da) | Tetracykliske arylcarbonylindoler med serotoninreceptor-affinitet til anvendelse som terpaeutiske midler, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende dem | |
| TW200608968A (en) | Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity | |
| DE50214537D1 (de) | C2-disubstituierte indan-1-one und ihre derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| EA200701052A1 (ru) | Новые производные замещённого арилпиперазина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |